EASME

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, that specializes in developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, addressing the needs of over 300 million patients worldwide affected by osteoarthritis. The company's flagship product, FibroFix, is a hydrogel implant designed to emulate human knee cartilage, enabling effective repair and regeneration of damaged tissues. Orthox offers several variations of FibroFix, including FibroFix Meniscus for meniscal cartilage repair and FibroFix Cartilage for articular cartilage damage. The implants promote integration with the body's cells, facilitating a return to active, pain-free living. With plans to expand its technology to other joints and additional applications beyond orthopaedics, Orthox is positioned to capitalize on the rapidly growing biomaterials market, projected to exceed $250 billion by 2025.

Vital Beats develops a medical platform for remote care of heart patients with pacemakers. The platform combines participatory design, data science, and machine learning to monitor cardiac devices remotely and predict health conditions.

Nuada is a company based in Braga, Portugal, specializing in the development of innovative systems designed to improve hand function. Its products cater to various sectors, including healthcare, sports, and professional activities. Nuada's solutions are characterized by their lightweight, compact, and non-intrusive design, employing thin, breathable, and flexible smart textiles that can be customized by users. The company aims to create a unique enhancement technology that serves as an essential wearable, designed for everyday use while being comfortable enough for individuals to forget they are wearing it.

Aromics Biotech is a biotechnology company focused on the discovery and development of innovative drugs and diagnostic methods aimed at addressing significant human diseases and enhancing patients' quality of life. The company specializes in creating anti-tumor and antiviral drugs while providing preclinical development services that involve tracking genomic and proteomic data. This approach enables biotechnologists to identify and validate therapeutic targets, supporting the clinical development process. Aromics Biotech emphasizes the importance of determining clinically predictive molecular endpoints, which assist physicians in managing diseases, guiding prescriptions, and monitoring patient responses to treatment. Through its commitment to utilizing OMIC technologies, Aromics strives to improve drug efficacy and reduce attrition rates in clinical trials.

Nasal is a technology-focused company that specializes in developing automated medical devices for the healthcare sector. It aims to enhance professional practices by providing tools that offer detailed insights into the structure and behavior of the nasal cavity. Through its innovative solutions, Nasal seeks to advance medical simulation technology, thereby assisting and training healthcare professionals. The company's efforts are geared towards improving the quality of care for patients and supporting the ongoing development of medical expertise.

Virtual Bodyworks is a company committed to improving lives by harnessing the power of scientifically-proven breakthrough technology. Their company specialises in immersive virtual reality focused on medical and psychological rehabilitation. Founded by scientists world renowned for their work in VR, we offer products that integrate a unique combination of computer science engineering, neuroscience and psychology.

MIMETAS B.V., founded in 2013 and based in Leiden, the Netherlands, specializes in the development of microfluidics-based culture plates designed for the cultivation and screening of three-dimensional organ and tissue models. The company's product line includes OrganoPlate 2-lane and 3-lane systems, which facilitate early-stage screening for drug efficacy and toxic side effects. By addressing the discrepancies between traditional in vitro and animal models and actual patient responses, MIMETAS aims to enhance the predictability of drug testing. Its OrganoPlates enable high-throughput screening of customized disease, toxicology, and transport models, thereby providing researchers and clinicians with innovative tools for compound testing and fundamental research.

SensoGenic Inc., established in 2016 and headquartered in Ness Ziona, Israel, specializes in developing diagnostic biosensors for food allergen detection. The company offers portable, handheld devices and digital analyzers designed for consumers, enabling them to test food items for allergens on-the-go. SensoGenic's innovative technology uses biosensors to detect allergens without physical contact, providing users with real-time results via a mobile application. This allows individuals with food allergies to safely consume meals at restaurants or social gatherings by avoiding allergic reactions.

Clover Bioanalytical is a bioinformatics company focused on developing software solutions for bioanalytical chemistry and clinical diagnostics, particularly utilizing mass spectrometry. Established by a team of Ph.D. graduates with extensive experience in both research and business, the company excels in providing advanced data processing capabilities and statistical analysis in the biomedical field. Clover's expertise encompasses mass spectrometry applications, medical image processing, and both univariate and multivariate statistical analyses, making it adaptable to a variety of needs within the healthcare sector. The company emphasizes a customer-oriented approach, tailoring its systems to meet client goals and ensuring scalability. Furthermore, Clover aims to address significant scientific challenges in collaboration with hospitals, research centers, and biotechnology firms, employing artificial intelligence to aid in the rapid identification of microorganisms and enhance diagnostic processes.

Biom'Up designs, develops and manufactures absorbable medical devices based on collagen technology for biosurgery. The company offers Hemoblast products for hemostasis and related laparoscopic applicators, and Hemosnow solutions for guided tissue regeneration, serving orthopedics, spine, cardiac, general, maxillofacial, dental and other surgical specialties. It markets its products in Europe and the United States. Biom'Up was founded in 2005 and is based in Saint-Priest, France.

Taliaz is revolutionizing the treatment and management of mental health disorders with PREDICTIX. PREDICTIX is a CE registered product that provides an advanced decision support software for psychiatrists and general practitioners. Harnessing artificial intelligence (AI), PREDICTIX can enable easy, effective and rapid patient assessment, improved prescribing precision and management for a wide range of mental health conditions. PREDICTIX understands that mental health disorders are multifaceted and unique. Combining data science with machine learning, PREDICTIX translates complex genetic, metabolic, demographic and clinical data into an easy-to-use assessment and prescribing support tool. Starting in the field of depression where the right antidepressant is only prescribed in 49% of cases (Chekroud et al., 2016), PREDICTIX improves treatment prescribing accuracy by 47% to achieve 72% prescribing accuracy*. PREDICTIX PRODUCTS - PREDICTIX Digital – 30% improvement in prescribing accuracy*. Combines AI analysis of patients’ clinical and demographic data to support doctor prescribing decisions. - PREDICTIX Genetics – 47% improvement in prescribing accuracy*. Further optimizes treatment decisions by combining a patient’s DNA analysis with AI. PREDICTIX is an ideal software solution for payors, providers, DNA laboratories and telemedicine providers to improve patient outcomes, reduce costs and expand service offerings in the mental health space. PREDICTIX is commercially available in Europe. Learn more at predictix.ai. *Based on a retrospective analysis of four STAR*D study medications. STAR*D is one of the world’s largest prospective studies for optimal antidepressant administration. Disclaimer: Taliaz is developing the PREDICTIX Genetics and PREDICTIX Digital products. PREDICTIX (Genetics) Antidepressant is currently available for commercial use in the EU and Israel. Outside of the EU and Israel, PREDICTIX Genetics products are currently limited by law for investigational use only. PREDICTIX Digital products are currently limited by law for investigational use only.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, that specializes in developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, addressing the needs of over 300 million patients worldwide affected by osteoarthritis. The company's flagship product, FibroFix, is a hydrogel implant designed to emulate human knee cartilage, enabling effective repair and regeneration of damaged tissues. Orthox offers several variations of FibroFix, including FibroFix Meniscus for meniscal cartilage repair and FibroFix Cartilage for articular cartilage damage. The implants promote integration with the body's cells, facilitating a return to active, pain-free living. With plans to expand its technology to other joints and additional applications beyond orthopaedics, Orthox is positioned to capitalize on the rapidly growing biomaterials market, projected to exceed $250 billion by 2025.

AmyPore is a biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases, specifically Alzheimer's and Parkinson's. Its lead product, AmyP53, is a chimeric peptide created using artificial intelligence applied to molecular neuroscience. This groundbreaking drug targets a common mechanism underlying both diseases by blocking the formation of neurotoxic structures, specifically oligomers of amyloid proteins, which are responsible for their progression. AmyP53 represents a novel therapeutic class, being the first molecule capable of addressing the shared pathophysiological aspects of Alzheimer's and Parkinson's diseases, thus providing new hope for patients affected by these conditions.

Brainmarc Ltd. is a company that specializes in developing a digital platform for cognitive remediation, utilizing its proprietary Brain Engagement Index (BEI) technology. Founded in 2013 and headquartered in Yokne'am, Israel, with an additional office in Hoboken, New Jersey, Brainmarc's platform employs electroencephalography (EEG) sensors to monitor brain engagement and mental activity. The technology provides insights into patients' attention levels during cognitive exercises, offering a more accessible alternative to traditional multi-electrode EEG systems. Brainmarc's innovative approach has demonstrated significant efficacy in treating cognitive impairments, with its solutions validated through numerous patient cases in clinical settings across the United States, Canada, the European Union, and Israel. The company aims to enhance the understanding and management of cognitive and mental disorders through its therapeutic products.

Healthplus.ai leverages electronic health record data to predict post-surgical complications, empowering healthcare professionals to proactively manage patient care, reduce complication impacts, improve outcomes, and lower costs.

CSF-Dynamics is developing a new type of hydrocephalus shunt that overcomes the major issues of current shunts on the market. The shunt is currently undergoing clinical testing. CSF-Dynamics expects the shunt to be approved for clinical use by end of year 2021.

Picterus is developing an app to diagnose jaundice in newborns, aiming to reduce the global infant mortality associated with this condition. The platform uses a patented color calibration card and smartphone camera for accurate image capture, providing healthcare professionals and caregivers with a reliable tool for early detection and timely intervention.

Surgitate is a Turkish startup founded by Ozge Akbulut (PhD in Materials Engineering) and Barkın Eldem (MD, Thoracic Surgeon). They manufacture synthetic models for medical professionals and students to practice surgical procedures realistically. Their product range includes skin, breast, and vascular models designed to mimic incision, dissection, and suturing. Surgitate benefits from investments by Farplas, a leading automotive parts manufacturer, which aids in mass production processes, and Inovent, Turkey's first tech commercialization accelerator, facilitating connections with potential investors and customers.

Radiobotics is a technology company focused on developing advanced machine learning algorithms that assist healthcare professionals in analyzing medical images, particularly x-rays of bones and joints. By automating routine tasks and generating radiology reports, the company's solutions facilitate quicker access to critical diagnostic information, thereby enhancing the quality of medical decision-making. Radiobotics aims to support doctors by streamlining the image analysis process, ultimately contributing to improved patient outcomes through more accurate and timely diagnoses.

MaxWell Biosystems is a neuroscience-focused electronics and biotechnology company that develops instrumentation and solutions to advance neuroscience research and accelerate preclinical drug discovery. It provides functional cell imaging and electrophysiology platforms to study cellular function and network activity. The flagship MaxOne platform is a CMOS-based high-density microelectrode array that records and stimulates electrogenic cells in vitro, featuring thousands of electrodes, low-noise readout channels and multiple stimulation channels to enable single-cell and network parameter extraction for phenotypic screening and drug toxicity and efficacy testing. The integrated platform combines a sensor chip, acquisition hardware and software to deliver accurate results and speed up the characterization of cell function from months to weeks. The company, founded in 2016, is based in Zurich, Switzerland.

Mecwins develops nanotechnological platforms for sensitive immunoassays, focusing on applications in oncology, cardiovascular disease, and infectious diseases. Their technology improves healthcare outcomes for at-risk populations.

Raylytic GmbH is a software development company specializing in automated medical image analysis and clinical data extraction. Founded in 1999 and headquartered in Leipzig, Germany, with additional offices in Magdeburg, Raylytic offers the UNITY platform, which provides a fully integrated solution for clinical trial management and medical data collection. This web-based platform streamlines the setup and execution of clinical data collection tasks, including the management of case report forms and patient-reported outcome measures, while employing advanced algorithms for the precise analysis and quantification of radiological images. Raylytic's services encompass a range of activities, including clinical trials for medical devices, independent qualitative analysis, development of radiographic protocols, quality assurance, data management, and statistical reporting. The company's innovative approach combines industrial and medical image processing with machine learning, enabling efficient and accurate evaluation of medical images for evidence-based medicine and regulatory compliance.

BalanSeat is a medical device developed by MoPair Technologies Ltd., a company founded by a Feldenkrais practitioner with extensive experience in treating neurologically impaired patients, including those with Multiple Sclerosis, Post-Stroke effects, and Parkinson’s disease. The device is designed specifically for the elderly and individuals with neurological impairments, aiming to enhance walking quality, improve balance, and reduce the risk of falls. BalanSeat achieves this by applying rotational movement between the pelvis, trunk, and thighs, which emulates normal walking patterns while the user remains seated. This innovative approach helps older adults regain essential balance and upper-body rotational movement, contributing to their overall mobility and safety.

Diapath S.p.A. is a privately held company that specializes in the anatomic pathology sector, providing a range of high-quality products and customized services to hospitals and laboratories globally. The company manufactures reagents, medical instruments, and consumables designed for modern anatomical and cytology laboratories. Its product lineup includes high-tech instruments, stains, tissue processing dyes, and microtomy supplies, all developed to meet rigorous quality standards. With a commitment to innovation and reliability, Diapath aims to establish itself as a leading brand in anatomic pathology, emphasizing customer needs and delivering tailored solutions.

EpiGuard is a Norwegian company founded in 2015 by a group of doctors from Oslo University Hospital, in collaboration with Inven2, Eker Group, and Hansen Protection. The company specializes in the development and manufacturing of medical transportation systems designed to facilitate the safe transfer of patients with contagious diseases. EpiGuard's flagship product is a single-patient isolation and transport system that effectively prevents the spread of infection from infected patients and safeguards them from contaminated environments. This innovative solution not only protects medical staff but also ensures that patients receive appropriate treatment during transportation. With a strong foundation in various medical fields, including intensive care and infectious diseases, EpiGuard leverages its expertise to enhance patient safety and care in challenging medical scenarios.

Allergy Data Laboratories continues to manage and support the Allergome project.

Vetherapy Corp., established in 2015 and headquartered in San Francisco, specializes in veterinary regenerative medicine and tissue engineering. The company produces stem cell therapy products for cats, dogs, and horses, focusing on accelerating wound healing and treating autoimmune and inflammatory diseases. Vetherapy's offerings include stem cell and platelet-rich plasma (PRP) banking services, ensuring veterinarians have access to safe and efficient products for various animal health conditions.

Immundnz is an immunology CRO specialised in immune modelling, immune response and tissue damage analysis, in vivo and in vitro cell culture systems for preclinical drug research and development. We are different because we are experienced scientists who will design an experimental model and use customised assays as well as standard assays tailored for the right solution for your problem. We will develop novel assays in our laboratory to meet your specific and unconventional need.

Scandion Oncology A/S is a biotechnology company based in Copenhagen, Denmark, focused on developing innovative treatments for chemotherapy resistance in cancer patients. Founded in 2017, the company is advancing several drug candidates, including SCO-101, which is currently undergoing Phase II clinical trials for breast and colorectal cancers, and SCO-201, which is in late pre-clinical development for solid tumors. Scandion Oncology aims to improve the outcomes and quality of life for cancer patients facing the challenge of drug resistance, a significant obstacle in oncology that affects approximately half of all patients undergoing chemotherapy. The company has established collaboration agreements with the University of Copenhagen to co-develop SCO-301, a candidate designed to counteract drug resistance, and is also exploring the potential of combining SCO-101 with Alligators mitazalimab to enhance anti-tumor effects in resistant tumor models.

Oxford Endovascular develops a neurovascular device to treat brain aneurysms. The device uses origami-inspired engineering with a laser-cut metal alloy that has shape-memory, enabling a catheter-delivered implant to expand into a tiny mesh tube that conforms to the vessel. By diverting blood flow away from the aneurysm, it promotes healing and reduces the risk of rupture.

Cardioset Medical is a group of scientists and business people who strive to make a life-changing impact on patients suffering from heart failure lung edema. With over 15 years of research and development we now have the solution that can literally revolutionize millions of HF patients' lives by enabling them to self-monitor their lung edema state and detect small changes at an even earliest stage.

Vibrosonic GmbH is a company specializing in the development, production, and marketing of advanced hearing solutions aimed at addressing various levels of hearing impairment. As a spin-off from the Fraunhofer Project Group for Automation in Medicine and Biotechnology and the University ENT Clinic in Tübingen, Vibrosonic focuses on innovative technologies that enhance the auditory experience for users. The company has created hearing contact lenses that utilize microsystem technology and a piezoelectric principle, enabling sound transmission through vibrations directly to the eardrum. This approach offers a discreet alternative to traditional hearing aids, improving comfort and usability for individuals with hearing loss.

RemAb Therapeutics specializes in the development of polymeric glycoconjugate molecules aimed at addressing nosocomial infections. The company's innovative technology focuses on eliminating non-neutralizing natural antibodies that hinder the immune system's natural response and promote pathogen proliferation. By targeting these antibodies, RemAb Therapeutics seeks to provide medical practitioners with effective new strategies for both treating and preventing a range of pathological infections, enhancing patient outcomes in the process.

KronosDNA Srl is a young biomedical company specialized in the reproductive genetics and founded by a team of women, researchers with technical-scientific and managerial expertise. KronosDNA is committed to improving maternal and new born healthcare and facilitating advances in laboratory medicine thanks to the development, prototypization and validation of diagnostic tools to support professionals in the reproductive medicine field.

liberDi is an Israeli company that specializes in developing portable automatic peritoneal dialysis systems for patients with end-stage renal disease. The company has created a comprehensive Digital Dialysis Clinic that enables patients to manage their own dialysis care with the assistance of an Intelligent Dialysis Assistant and remote medical supervision. This innovative self-care system allows patients to perform dialysis conveniently from various locations, such as their homes or while traveling, thereby enhancing their quality of life. Founded in 2014, liberDi aims to transform the traditional dialysis model by providing a safe, patient-friendly alternative to in-clinic care. The company's technology not only empowers patients but also helps clinics optimize their operations, improve service quality, and reduce costs, establishing a holistic platform for renal patients and their caregivers.

TomoWave is a company focused on developing innovative imaging technologies for clinical medicine and preclinical research. Utilizing its proprietary optoacoustic and laser ultrasonic imaging modalities, TomoWave aims to enhance cancer detection, guide medical interventions, and monitor the effectiveness of cancer therapies. The company's technology, which captures images by "listening to the sound of light," allows for highly detailed visualization of tissues, particularly in relation to vascular and blood-related conditions. Founded by Dr. Alexander Oraevsky, a pioneer in biomedical optoacoustics, TomoWave has a strong emphasis on generating intellectual property and advancing it from concept to validated clinical prototypes. The company is committed to bringing its technologies to market through appropriate regulatory certifications, thus contributing to improved diagnostic capabilities in healthcare.

Double Bond Pharmaceutical is a pharmaceutical company that develops and commercializes innovative first-in-class therapies for the treatment of cancers, infections, autoimmune diseases, and other life-threatening disorders. It aims to provide patients and markets with safer, more effective products in areas where medical needs remain unmet.

ScarTec Therapeutics develops novel peptide-based technology for scar-free healing.

Hephaistos Pharma is a biotechnology company developing an immunotherapy platform aimed at producing advanced oncology treatments. Its platform enhances commercialized antibodies by stimulating the immune system, turning 'cold' tumors into targets for immune response.

Mimetis Biomaterials SL is a Spanish company founded in 2013, specializing in the design and manufacture of biomimetic bone graft substitutes for medical applications in dental, craniomaxillofacial, and orthopedic sectors. The company focuses on creating synthetic bone grafting solutions that mimic the properties of natural bone, thereby facilitating the colonization of grafts by bone cells and improving outcomes in complex cases. Mimetis offers a range of products, including biomaterial granules and patient-specific 3D-printed grafts, to address various bone defect filling needs. In addition to its product offerings, the company provides consulting, original equipment manufacturing, and co-development services to clinicians. Mimetis Biomaterials was previously known as Subtilis Biomaterials S.L. until its name change in January 2016 and is headquartered in Barcelona, Spain.

BioCom is a highly innovative Company in the biomedical sector, focused on research, development and manufacture of cutting-edge medical devices, as well as the development of new technologies for surgery, diagnostics and biomedical research.

Sepsia Therapeutics is developing new broad-spectrum drug and cellular therapies against sepsis, a life-threatening condition caused by the host response to an infectious agent, mostly bacterial and fungal. Their strategies are based on the host’s scavenger-like receptors present on lymphocyte cell surfaces, which bind to and neutralize the conserved inflammation-promoting structures of bacteria and fungi that cause sepsis. These structures provide novel therapeutic targets aimed at both, microbial virulence factors and host inflammatory and immune mediators,

E-Motion Medical Ltd was founded in 2011 by a pioneering multidisciplinary team with extensive experience in medicine, science, management and business. The E-Motion System™ delivers unique patterns of stimulation to the esophagus, thereby generating contractions, which restore natural function to the digestive system and promote motility throughout the gastrointestinal tract. The stimulation is applied to the esophagus using their proprietary E-Motion Tube™, which can also double as a feeding tube, and is easily placed in the same manner.

OnDosis is a Swedish company founded in 2017, focusing on personalized medicine through its innovative dosing technology. The company specializes in delivering flexible and individualized dosing of oral medications, which are formulated as micro units like pellets, granules, mini tablets, or powders. By integrating digital technologies with traditional drug-based treatments, OnDosis aims to enhance disease management and improve patient adherence, particularly for conditions such as ADHD, pain management, and immunosuppression in organ transplant recipients. Their approach addresses the limitations of conventional tablets or capsules, providing greater convenience and improved health outcomes for patients. The technology developed by OnDosis is rooted in research from AstraZeneca and is supported by a network of strategic partners that assist in various core functions, including formulation, device development, and regulatory compliance.

Bioithas is a medical research company focused on developing natural treatments aimed at improving health and quality of life. The company dedicates its efforts to conducting rigorous clinical trials to create personalized therapies that address the root causes of health issues rather than merely alleviating symptoms. By directing research toward unique biotechnological advancements, Bioithas seeks to generate valuable projects that contribute to meaningful scientific outcomes, ultimately enhancing the well-being of individuals.

Respinova is a developer of innovative non-invasive inhalation devices aimed at treating respiratory disorders, particularly chronic obstructive pulmonary disease (COPD). The company's flagship product, PulseHaler, utilizes a proprietary technology that generates dynamic air pressure pulses to target the core pathophysiology of COPD. These pressure pulses are designed to travel rapidly through the lung's airways, creating gentle dilating forces that help open collapsed airways and facilitate the clearing of mucus. By smoothing and spreading the mucus lining on the airway walls, PulseHaler assists in airway clearance and reduces the likelihood of airway re-closure, providing an effective treatment option for COPD patients.

EarWays Medical Ltd. is an innovative company focused on developing effective ear-care solutions aimed at improving the well-being of both children and adults. The company specializes in a medical device designed for the removal of earwax, utilizing a clinically proven and patented technology that features a flexible coated helical tip for easy navigation within the ear canal. This device facilitates cerumen extraction, management, and addresses earwax impaction, which can lead to temporary hearing loss. EarWays Medical offers user-friendly ear care products that are suited for both clinical environments and home use. The company is supported by a team of experts in bioengineering, medical devices, ear surgery, and hearing rehabilitation, positioning it to significantly enhance the accessibility and effectiveness of ear care solutions.

Anima is a unique AI-based short-screening solution for early detection of children suffering from sexual abuse. The tool will screen and identify experience of sexual abuse at an early stage, thus prevent further abuse and providing treatment. This in turn will reduce future mental and physical negative consequences of the abuse.

ODI Medical is a developer of advanced medical technology focused on the bedside evaluation of circulatory failure through the assessment of microcirculation. The company's innovative devices streamline the collection of microvascular data, facilitating a variety of clinical applications. These include monitoring patients on mechanical heart and lung machines, evaluating the toxicity of chemotherapy, early detection of evolving sepsis, and monitoring chronic wounds. Additionally, ODI Medical's technology supports mass screening for infectious conditions such as Ebola, bird flu, and epidemic meningitis. By utilizing non-invasive methods, the company enables medical researchers to enhance patient therapy through a better understanding of microcirculation.

Samplix is a biotechnology company based in Herlev, Denmark, that specializes in advanced sample preparation for single DNA and RNA molecules. The company has developed the proprietary Xdrop™ technology, which utilizes a unique "water-oil-water" droplet formation to create millions of reaction chambers for handling individual DNA molecules. This innovative technology allows for targeted enrichment of large DNA fragments, addressing the limitations of existing multi-molecule preparation methods. By enabling precise and sensitive sample preparation, Samplix empowers researchers to conduct more informed studies, facilitating the sequencing of genetic regions critical for understanding virus integration and minimizing unintended CRISPR edits. The Xdrop™ system includes both the instrumentation and consumables needed for effective single-molecule analysis, thereby enhancing the ease of use and efficiency in molecular research.

Dytective is the scientifically validated reference tool for detection and improvement of skills related to dyslexia. Dytective combines two scientifically validated tools developed by Change Dyslexia. In only 15 minutes, through a series of tests, according to your age and abilities, Dytective Test detects if you are at risk of having dyslexia. With DytectiveU you will improve your reading and writing skills while having fun playing.

Domalys SAS is a French company established in 1990, specializing in solutions and products aimed at improving the quality of life for elderly individuals and their caregivers. The company designs and manufactures a range of innovative products, including the Aladin lamp and telecare assistance system, Domalys tracking software, Complys customized tables, and Modulys hanging tables. These products are specifically developed to enhance safety and well-being in care environments, such as nursing homes, by detecting early warning signs of health issues and providing intelligent lighting solutions. Domalys's offerings are co-designed with care staff, ensuring they meet the unique needs of elderly users and their surroundings, thereby helping to prevent falls and enrich daily living experiences.

Eden Microfluidics is a young innovative company founded in 2017. The company aims to provide advanced and certified materials, microfabrication and microfluidics solutions to both researchers and industrial partners. Eden Microfluidics is driven by a team of talented and passionate scientists, innovators and entrepreneurs, thriving to develop radical microfluidic solutions, for biomedical to environmental challenges. All together, they assemble a large IP portfolio of polymer and epoxy formulations, cellular micro-environment and microfluidic remediation systems. Eden Microfluidics is here to offer you access to the latest, up-to-date microfluidic science and technology.

VisionHealth GmbH is a healthcare software company based in Munich, Germany, founded in 2017. It specializes in developing digital solutions for patients with chronic respiratory diseases, such as asthma and COPD. The company's primary product, Kata, is an artificial intelligence and machine learning-based application that connects respiratory patients with healthcare professionals. Kata enhances inhalation therapy by training patients on the effective use of their inhalers, utilizing advanced object recognition and movement interpretation technologies. This innovative approach aims to improve patient adherence to inhalation therapy, ultimately reducing hospital visits and lowering overall therapy costs for chronic lung conditions.

Cytox Limited is a company focused on developing innovative products and services for the diagnosis and treatment of neurodegenerative disorders, particularly Alzheimer's disease. Established in 2004 and headquartered in Birmingham, UK, with additional offices in Manchester and Oxford, Cytox has created a genetic-based blood test that assesses the risk and early diagnosis of Alzheimer's disease, which currently affects millions worldwide. The company employs cellular and genetic assays to identify early cell cycle deficits in patients, aiding pharmaceutical and biotechnology companies in clinical trials and drug development for Alzheimer's and mild cognitive impairment. Cytox's strategic partnership with Affymetrix, part of Thermo Fisher Scientific, enhances its capabilities in delivering these assessments and supporting the development of novel therapeutics.

Diabeloop is a medical device company based in Grenoble, France, specializing in innovative solutions for diabetes management. Founded in 2015, the company focuses on developing a closed-loop system that automates insulin delivery for individuals with type 1 diabetes. Its AI-based blood sugar monitoring device integrates a sensor that continuously measures glucose levels, a pump that administers insulin, and a smartphone application that connects these components through an embedded algorithm. This technology aims to enhance the treatment experience by reducing the mental burden on patients, allowing them to manage their condition more effortlessly and live their lives with greater freedom.

Clarify Analytical is an innovative service providing start-up committed to develop state-of-the-art mass spectrometry based methodologies.

Vetbiobank is a biotechnology company specializing in veterinary regenerative medicine. It focuses on developing and providing clinical-grade cell and tissue products derived from neonatal stem cells to veterinarians, aiming to improve animal care by managing chronic inflammatory conditions affecting joints, skin, digestive system, and mucous membranes.

Smart Octopus Solutions is a technology company that specializes in identification technologies and digital process optimization across industries. It provides real-time gift card tracking, loyalty program management, RFID-based event management, and multi-channel marketing automation, with customizable loyalty programs to help clients streamline operations and improve customer engagement. In event contexts, its solutions support attendee tracking, credentialing, mobile apps, lead retrieval, and marketing automation to enhance exhibitor and attendee interactions.

Delta Diagnostics, founded in 2018 as a spin-off from TNO – The Netherlands Organisation for Applied Scientific Research, specializes in the commercialization of advanced biosensor technology. The company focuses on developing photonic biosensors that integrate optical chips with waveguides to facilitate multiplexed biosensing. This technology enables real-time monitoring through highly sensitive refractive index sensors, allowing for label-free biosensing. Delta Diagnostics aims to provide rapid, sensitive, and cost-effective solutions that can significantly enhance research in the Life Sciences sector. By enabling accurate measurement of multiple biomarkers within minutes, the company aspires to drive new discoveries and foster the development of innovative diagnostics.

Minnemera, established in 2017 and based in Stockholm, Sweden, specializes in developing digital cognitive screening tools. These tools automatically compare an individual's test results with normative data and their own baseline values to detect abnormalities, aiding in early detection of neurological conditions.

Metys Pharmaceuticals is focused on developing MP-101, a small molecule drug aimed at preventing and treating chemotherapy-induced peripheral neuropathy, a common and distressing side effect of cancer treatments. MP-101 functions as an orally-active modulator of glutamate signaling in the spine and brain, a pathway that has been targeted for new central nervous system therapies. The drug is derived from a patent-pending non-racemic mixture of the enantiomers of dimiracetam, which has demonstrated enhanced pharmacological potency compared to traditional racemic mixtures. Metys Pharmaceuticals has secured exclusive global rights to racemic dimiracetam from Neurotune AG, along with comprehensive regulatory study data to support future clinical trials for MP-101. The company aims to leverage this data to advance its innovative approach in addressing neuropathic pain and other central nervous system disorders.

Founded in London in 2017, Limbic specializes in developing software solutions for mental health. They create AI-driven agents to assist in patient intake, triage, screening, and therapy, aiming to enhance the efficiency of healthcare providers and improve patient outcomes.

Gedea Biotech develops an antibiotic-free treatment for vaginal fungal infections using its substance GA101. This natural substance lowers pH, provides physical barrier protection, and inhibits biofilm formation. The company's first product is a topical treatment for vaginal fungal infections.

PreOmics GmbH is a biotechnology company based in Planegg, Germany, specializing in mass spectrometry (MS)-based proteomics. Founded in 2016 as a spin-off from the Max-Planck Institute of Biochemistry, PreOmics develops innovative tools and technologies aimed at enhancing protein analysis for researchers worldwide. The company's flagship product, the iST Kit, facilitates rapid and reproducible preparation of peptide mixtures from various starting materials, streamlining the sample preparation process within just one hour. PreOmics also offers high-throughput processing accessories and a robust platform that leverages liquid chromatography coupled with mass spectrometry to enable comprehensive protein identification, quantification, and analysis of post-translational modifications. Through its advanced solutions, PreOmics supports the scientific community in accelerating discovery and understanding of protein interactions and functions.

CMS Dental provides products and treatment concepts for the modulation of biofilm and for preventing infectious conditions of the oral cavity. In their field of endodontics, they developed root-filling systems. Their oral cavity is associated with the development of systemic chronic diseases including cardiovascular disease, alzheimer's, oral, pancreatic cancer, and arthritis.

EmeraMed Limited is a privately held biotechnology company based in the Republic of Ireland, with operations in Ireland, Sweden, and the United States. The company's ownership group consists mainly of physicians, dentists, and patients who have previously used its products as dietary supplements. EmeraMed is focused on developing a lipophilic antioxidant capable of penetrating the blood-brain barrier. The company's primary goal is to chelate free iron and various heavy metals, including mercury and lead, which can generate harmful free radicals. By addressing these issues, EmeraMed aims to help healthcare providers restore normal mitochondrial function and enhance overall health.

ChemiCare is a biotech company founded in 2016 that focuses on discovering and developing therapies for calcium-related rare genetic diseases. It aims to restore normal intracellular calcium levels by modulating store-operated calcium entry with drug-like modulators, crafted through click chemistry to enable exploration of chemical space and rapid refinement of candidate compounds, thereby accelerating drug discovery and development.

Founded in Paris, France in 2014, Eligo Bioscience specializes in developing innovative antimicrobials called Eligobiotics. These are protein-based nanodelivery vectors that employ a synthetic circuit encoding for a programmable RNA-guided nuclease, targeting bacteria based on their genome. The company's applications span therapeutics, cosmetics, biodefense, and more.

InSCREENeX GmbH is a biotechnology company located in Braunschweig, Germany, and operates as a spin-off of the Helmholtz Centre for Infection Research, founded by Dr. Roland Schucht. The company specializes in developing cellular screening technologies that aim to expedite the drug discovery process for pharmaceutical and drug development firms. By utilizing advanced genetic manipulation techniques, InSCREENeX creates innovative and user-friendly mammalian cell systems that serve as effective decision-making tools in drug development. These systems are designed to enhance biological relevance and convenience, addressing the time and cost challenges associated with biopharmaceutical drug discovery. Additionally, InSCREENeX is developing complementary technology platforms that facilitate the generation of cell lines for primary screening and the design of physiologically relevant cell types for secondary screening and profiling.

Cellestia Biotech AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative anti-cancer therapies. Founded in 2014 as a spin-off from EPFL in Lausanne, Cellestia focuses on its lead candidate, CB-103, an oral pan-NOTCH inhibitor designed to treat NOTCH-dependent leukemia, lymphoma, and solid tumors. The company is committed to advancing its research and development pipeline, which includes novel transcription factor inhibitors for oncology, autoimmune, and inflammatory disorders. Cellestia aims to enhance patient outcomes by developing NOTCH-specific biomarkers and diagnostics for more effective patient selection. With its emphasis on modulating pathogenic gene expression through selective inhibition of transcription factors, Cellestia is dedicated to pioneering breakthroughs in cancer treatment.

BioSpeedia develops and manufactures a vitro diagnostics rapid test kits and ELISA kits for medical professionals.

Saphenus has decoded phantom pain and enlarge gait stability through the sense of touch idea and the findings of the medicine nobel price 2021. Globally, millions of amputees face the devastating challenge of phantom pain, with no effective solution available until now. This constant, debilitating pain significantly impacts their quality of life. Saphenus has developed a groundbreaking technology that not only decodes phantom pain but also enhances mobility and stability through an innovative sensory feedback system, redefining what prosthetics can achieve. The urgency of our approach is underscored by the ongoing crisis in conflict zones like Ukraine-Russia and Israel-Palestina. These individuals urgently need faster, pain-free, and effective prosthetic solutions. With the establishment of our partnership with Ternopil Medical University in 2024, Saphenus is uniquely positioned to bring its innovation to those who need it most, offering renewed hope and quality of life. https://www.ukrinform.ua/rubric-regions/3916291-u-ternopoli-vijskovi-otrimali-innovacijni-priladi-do-proteziv-vid-avstrijskoi-kompanii.html Our technology is not just a medical breakthrough but a humanitarian imperative, poised to transform the lives of millions worldwide. Saphenus was awarded 2024 from the European Institute of Technology as one of the 6 best medtech startups in Europe.

OmniSpirant develops regenerative gene therapies with the potential to transform respiratory medicine.

Segmentum Imaging is a brand new app allowing you to count samples more quickly than traditional methods have previously allowed, whilst releasing you from the confines of the lab. Do your work conveniently, increasing your output and decreasing your time spent on repetitive actions. The adoption of digital pathology has been increasing dramatically. It is being used for more convenient diagnosis, easier sharing of images between consultants, large-scale collection for research purposes and in the creation of online virtual archives, critical in teaching and multi-centre research. Whilst the tools for researchers to utilise digital images have become very advanced, they are often very expensive and are commonly based in individual laboratories. This can easily result in considerable bottlenecks in use and limitations of access often lead to these facilities being simultaneously very costly but under-utilised.

Nateo Healthcare is a Toulouse, France-based medical technology company that designs, develops, and manufactures connected devices and software for obstetrics and gynecology. Founded by obstetricians, gynecologists and medical technology specialists, the company focuses on portable fetal monitoring solutions, including compact mobile fetal heart and uterine activity monitoring systems, and remote patient monitoring for maternity care. Its products enable continuous fetal heart rate and uterine activity assessment, support telemonitoring for home use or hospital settings, and aim to optimize bed utilization in maternity wards while enhancing patient well-being through more flexible care. By integrating wireless connections and real-time data, Nateo Healthcare seeks to provide clinicians with mobile, connected CTG monitoring capabilities and to expand access to monitoring in hospitals and at home.

Magentiq Eye Ltd., established in 2014, specializes in developing AI-driven medical devices for endoscopic procedures. Its flagship product is the Automatic Polyp Detection System (APDS), which uses computer vision and deep learning to assist doctors in real-time colonoscopy examinations, aiming to reduce polyp miss-rates and improve patient outcomes.

Deneb Medical develops a laser-based robotic surgery system and a robotic platform for use in neurosurgery, craniofacial and head and neck surgery, urology, and general surgery. The system uses optical and photonic techniques for tissue ablation and includes three-dimensional visualization, augmented reality guidance, and robotic assistance to enable more accurate, efficient, and minimally invasive procedures, with the goal of improving patient outcomes.

Cambridge Mask Co specializes in the manufacturing and distribution of advanced consumer pollution masks that utilize military-grade filter technology originally developed for chemical, nuclear, and biological warfare protection. These masks are designed to filter nearly 100% of viruses, bacteria, gases, and particulate pollution, providing users with effective protection against air pollution. Available in a variety of sizes and patterns suitable for all ages, Cambridge Mask Co serves a diverse clientele, including organizations such as the United Nations, NetJets, and British Airways. The company's commitment to health and safety is evident in its use of activated carbon cloth for superior filtration, ensuring that users can breathe cleaner air and maintain a healthier lifestyle.

7scientists current academic research findings into practical solutions.

ImmuneBiotech AB, established in Lund, Sweden in 2013, specializes in the research and development of novel microbiome therapeutics. The company focuses on probiotic lactic acid bacteria and synbiotic formulations that target the gut microbiota and the immune system, aiming to prevent and treat autoimmune and chronic inflammatory conditions such as multiple sclerosis, rheumatoid arthritis, and type 1 diabetes.

eLive Ecosystem specializes in developing innovative solutions aimed at preventing long-term diseases through advanced technology. The company has created an artificial intelligence-based medical device specifically designed for the self-measurement of sleep apnea, addressing diagnostic gaps and enhancing treatment monitoring. By integrating medicine, genomics, and advanced sensor technology, eLive aims to alleviate the pressures on healthcare systems caused by demographic changes and aging populations. Their platform focuses on enabling healthcare professionals to efficiently and cost-effectively manage disease prevention and treatment, ultimately improving patient outcomes on a global scale.

Aspivix develops innovative medical devices aimed at enhancing safety and comfort in gynecological procedures. Its flagship product, CAREVIX, employs suction technology to gently stabilize the cervix during procedures, reducing pain and minimizing risks such as bleeding and infections.

Sinfonia Biotherapeutics is pioneering the development of novel, bioreactor-delivered drug treatments for familial & genetically-defined orphan neurodegenerative disorders within frontotemporal lobar dementia (FTD), Alzheimer’s and Parkinson’s disorders. Just as cancer is composed of many different subtypes, they know dementia is as well. Thus, to succeed where others have failed in developing dementia treatments, they are developing breakthrough biologic therapies that target familial dementia subtypes with underlying disease mechanisms that are known.

CyTuVax is a clinical stage vaccine company focused on addressing significant medical needs through innovative vaccine solutions. The company collaborates with leading European research institutions to leverage its proprietary adjuvant technology, which enhances the effectiveness of vaccines by inducing robust humoral and cellular immune responses. This technology not only improves the quality of standard vaccines but also reduces the number of required doses. CyTuVax develops both prophylactic vaccines targeting viral and bacterial pathogens and therapeutic vaccines aimed at treating cancer. With a strong emphasis on patient-centered development, the company aims to deliver advanced vaccination strategies that meet critical health challenges.

Founded in 2015, Bambi Medical is a MedTech company dedicated to reducing pain and stress in premature infants while enhancing parent-child bonding. It specializes in designing, developing, and manufacturing innovative products for Neonatal Intensive Care Units.

Gondola Medical Technologies SA is a Swiss company dedicated to the research and development of innovative medical devices aimed at enhancing rehabilitation for individuals with neurological and osteoarticular conditions. Founded in 2011 and headquartered in Stabio, the company has created the GONDOLA medical device, which employs Automated Mechanical Peripheral Stimulation (AMPS) to address motor symptoms associated with Parkinson's disease. This non-invasive device targets issues such as freezing of gait, slowness of movement, and balance difficulties. The GONDOLA device is designed for short-term use, allowing patients to wear it on their feet for a few minutes, and can be utilized in both home environments and clinical settings. Regular use of the device, ideally twice a week, sustains its therapeutic benefits, which can last from three to five days after treatment.

TRiCares is a medical device company focused on creating innovative solutions for tricuspid valve regurgitation. The company specializes in developing a catheter-based valve replacement system that facilitates minimally invasive treatments for patients suffering from tricuspid insufficiency. By emphasizing anatomical conformation and user-friendly design, TRiCares aims to provide effective and durable treatment options that improve patient outcomes. Through its advancements in medical technology, TRiCares addresses a critical need in cardiology, enhancing the quality of care for those affected by this condition.

MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and personalized treatment of patients.

Eucardia specializes in the development of a groundbreaking medical device known as the Heart Damper. This minimally invasive implantable cardiac device is designed to address the needs of patients suffering from advanced heart failure. By offering a straightforward and cost-effective therapeutic solution, Eucardia aims to enhance both the duration and quality of life for these patients. Additionally, the Heart Damper contributes to lowering healthcare costs associated with advanced heart failure management, making it a significant advancement in cardiac care.

CRU network has been providing clinical research services to the pharmaceutical industry for over a decade and basic/academic research services since 2015. In the recent years next to the research activities many new healthcare services were initiated within the EU and in South-East Asia. CRU sites are located in Hungary, Ukraine, Germany, Vietnam and LAO PDR.

Mercurna B.V. is a biotechnology company based in Oss, Netherlands, founded in 2017. The company focuses on the synthesis of messenger RNA (mRNA) and the development of therapies aimed at treating chronic kidney diseases. As a startup in the biotech sector, Mercurna is dedicated to delivering innovative precision medicine solutions specifically designed for patients suffering from chronic kidney conditions.

Lab-on-Fiber develops, manufactures, and commercializes fiber-delivery and laser systems for minimally invasive surgery, including surgical and urology fiber probes. The company provides smart medical laser probes and systems designed to optimize energy delivery and safety during laser procedures. By measuring probe-surface temperature and shaping radiation profiles, Lab-on-Fiber aims to shorten operating times, improve treatment outcomes, and reduce the need for repeated applications. Based in Halle, Germany, the company targets procedures where precise light delivery and real-time feedback can enhance patient safety and procedural efficiency.

DermoSafe is a Swiss company founded in November 2012 by Philippe Held, located in Cheseaux, Switzerland. The company specializes in innovative products and services aimed at the early detection and management of melanoma. DermoSafe manufactures medical devices that capture high-definition dermoscopic images of moles and pigmented lesions, facilitating a straightforward process for general practitioners. Through a secure web application, practitioners can enter patient data and send images to dermoscopy specialists for analysis. These specialists provide their assessments in documented electronic reports, enabling healthcare professionals to identify melanoma at an early stage and effectively manage treatment.

omicX is a company based in Le Petit Quevilly, France, that operates a bioinformatics platform designed to facilitate access to biotechnology tools. Established in 2012, omicX aims to harness the growing collective intelligence in bioinformatics to leverage biological Big Data for various applications across biotechnology, life sciences, medicine, agriculture, and industry. Its primary offering, OMICtools, serves as a valuable resource for scientists and developers, providing information on tools for storing, processing, and sharing significant volumes of biological data. The platform also enables users to engage with the scientific community by posting questions, sharing expertise, and providing feedback on available tools. This innovative approach has positioned omicX as a trusted leader and global reference in the bioinformatics field, attracting users from prestigious universities, medical institutions, pharmaceutical companies, and the biotech industry.

Depixus specializes in advanced genomic analysis technology. Its innovative platform enables real-time, high-precision analysis of individual biomolecular interactions at scale. This allows researchers to uncover new biological pathways and disease mechanisms, facilitating the development of precision medicines.

Klaria Pharma Holding is a Swedish pharmaceutical company focused on rapid-acting products. It combines patented film-based technology that attaches to the oral mucosa with proven pharmaceuticals to form a drug delivery platform. The platform uses an alginate-based polymer film to enable absorption of an active substance through the oral mucosa, offering rapid onset and potential for diverse therapeutic applications.

RegStem is an early-stage biopharmaceutical company focused on repurposing existing molecules and developing new treatments within the regenerative medicine sector. The company specifically targets rare muscle and blood diseases that present significant unmet medical needs. Its research and development efforts are centered on innovative molecules intended for human therapies, including the repurposing of drugs aimed at reconstituting and repairing bone marrow during acute aplasia and promoting skin healing after scarring. By stimulating and controlling the differentiation of stem cells, RegStem aims to provide effective solutions for patients suffering from chronic skin conditions and other serious health issues.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Founded in 2015, ATXA Therapeutics is an Irish pharmaceutical company dedicated to developing novel small molecule drugs for treating pulmonary arterial hypertension (PAH). With a strong scientific foundation and over €15 million in grant funding, the company focuses on advancing clinical trials and securing marketing authorization for its therapies.